Terlipressin

Brevis descriptio:


  • Product nomen:Terlipressin
  • Cas No:14636-12-5
  • Formulae hypotheticae:C52H74N16O15S2
  • Pondus hypotheticum:1227.39 g/mol
  • Sequentia:H-Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys Pro-Lys-Gly-NH2 sal acetum
  • Aspectus:Pulvis albus
  • Applicatio:Acuti haemorrhagia varicealis (varices esophageales), syndrome hepatorenale, concussio septica Norepinephrine-resistentia - nondum approbata applicatio
  • Sarcina:Secundum Lorem scriptor requisitis
  • Product Detail

    Product Tags

    Keywords

    • Teripressin acetate
    • maxime parabilis pretium
    • CAS# 14636-12-5

    Velox Details

    • ProName: Teripressin
    • CasNo: 14636-12-5
    • Formulae hypotheticae: C52H74N16O15S2
    • Aspectus: cerussa
    • Applicatio: sanguinis varicealis acutum (esophageale ...
    • DeliveryTime: promptum sit amet
    • Sarcina: secundum necessitates
    • Portus: Shenzhen
    • ProductionCapacity: II Kilogram/mense
    • Puritas: 98%
    • Repono: II ~ VIII, custodita a lumine
    • Transportatio: per aerem
    • LimitNum: 1 Gram

    Superioritas

     

    professional peptide fabrica in Sina.
    princeps qualis est gmp gradus
    magnis auctoribus pretium
    nostra producta complectitur: mole generica apis peptidis, peptide medicatura, consuetudo peptides et peptides veterinarii.

     

    Singula

    Formulae hypotheticae

    C52H74N16O15S2

    Relativum Missae Molecularis

    1227.39 g/mol

    CAS-Number

    14636-12-5 (retia);

    Long-term PRAECLUSIO

    -20 ± 5°C

    Sequentia

    H-Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys Pro-Lys-Gly-NH2 sal acetum
    (Disulfide vinculum)

    Agri Application

    Sanguis acutus varicealis (varices esophageales)
    Syndrome hepatorenale
    Norepinephrine-repugnans offensus septic - nondum approbata applicatione

    Substantia activa

    TerlipressinEst synthetica analogia vasopressini et adhibetur ut medicamentum vasoactivum in administratione hypotensionis.
    Terlipressinsignificat prodrug, convertitur ad (Lys8) - vasopressin (LVP) post remotionem terminationis N-

    triglycine in vivo. Terlipressin actio longiorem durationem habet et profile melioris securitatis quam parentis compositi LVP.

     

    Societas Profile:

    societas nomen:Shenzhen JYMed Technologia Co.,Ltd.
    Annus Constitutus: 2009
    Capital: 89.5 Million RMB
    Acetatum oxytocinum, acetatis vasopressinum, acetatis Desmopressin, acetatis terlipressin, acetatis Caspofungin, micafungin sodium, acetatis eptifibatidis, acetatis bivalirudin TFA, Deslorelini acetatis, acetatis glucagonis, acetatis histrelini, acetatis Caspofunginin, aceta- tis aeteris, acetatis elixatae, acetatis Bivalirudin TFA, deslorelin acetatis, glucagon. Acetate, Goserelin
    Acetate, Argireline Acetate, Metrixyl Acetate, Snap VIII, ....
    Studemus continuas innovationes in nova synthesi technologiae peptide et processu optimizationis, et nostra turma technica supra decennium experientiae in synthesi peptide.JYM feliciter multum submisit.
    of ANDA peptide APIs et producta cum CFDA formata et plus quam quattuor patentes approbatae habent.
    Nostra planta peptide in Nanjing sita, provincia Jiangsu et facilitatem 30,000 metrorum quadratorum posuit in obsequio cum indice cGMP. Facilitas artificiorum ab clientibus tam domesticis quam internationalibus est audita et inspecta.
    Cum praestantissima qualitate, pretiosissima et validissima subsidia technica, JYM recognitiones non solum acquisivit pro suis Institutis Investigationis et industriarum pharmaceuticae, sed etiam unus factus est ex certissimis praebitoribus peptidum in Sinis. JYM dedicatum est unum esse provisor primarius peptidis mundi in proximo futuro.

  • Priora:
  • Next:

  • Epistulam tuam hic scribe et mitte nobis